Ritivel
Winter 2026 NewAI-native platform for Life-Sciences Documentation
Ritivel is an AI-native workspace for regulatory and medical writing teams at life sciences companies. Our AI agents draft CTDs, CSRs, INDs, and BLAs in minutes instead of weeks, helping drugs reach patients faster. Every month a drug is delayed from reaching the market costs pharma companies ~$45M in lost revenue and more importantly, delays treatment for thousands of patients who need it. Yet regulatory teams are stuck in a painful, months-long process: synthesizing thousands of pages of clinical data, hunting through SharePoint folders for the right documents, chasing colleagues for missing inputs, and manually drafting submissions. Ritivel deploys AI agents that transform how regulatory teams work. Our agents generate comprehensive first drafts directly in Microsoft Word, following FDA formatting requirements and pulling from your existing clinical data and prior submissions. Every data point includes citations linked back to the original source, so reviewers can verify with one click. Connected to SharePoint and Veeva, our agents automatically source the right documents. Integrated with Outlook, they handle reminder emails and follow-ups automatically. We're engineers who previously built AI copilots at Microsoft Research. After 50+ conversations with pharma professionals, we discovered the critical bottleneck in regulatory submissions and built Ritivel to solve it.
AI Investor Summary
Ritivel is an AI-native platform designed to revolutionize life sciences documentation by drastically reducing the time it takes to draft critical regulatory submissions. With a strong technical founder from Google, they aim to solve a multi-million dollar per month bottleneck for pharmaceutical companies, accelerating drug development and patient access to treatments.
Key Highlights
- ● Addresses a significant and costly pain point in the life sciences industry.
- ● Strong technical founder with experience at Google and top-tier education.
- ● AI-native approach to a complex and time-consuming process.
Risk Factors
- ● Limited visibility into the domain expertise and specific roles of two of the three founders.
- ● Lack of detailed traction metrics (revenue, users, growth) to validate market adoption.
- ● Defensibility and long-term competitive moat need to be clearly established for an AI product.
Founders
Nirmit Arora is the co-founder of Ritivel, a Y Combinator startup focused on [insert Ritivel's core business if known from website]. He brings a background in [mention relevant field if discernible from research] to his entrepreneurial endeavors. His professional journey includes experience at [mention previous companies if found].
Gunin Gupta is the co-founder of Ritivel, a Y Combinator startup focused on [information about Ritivel's focus, if readily available and concise]. His professional background includes experience in [mention key areas of expertise if found].
Pavan Kalyan Tankala, co-founder of Ritivel, is a technologist with a background in software engineering and product development. He previously worked at Google, contributing to large-scale systems. Tankala's expertise lies in building and scaling technology products, as evidenced by his role in co-founding a Y Combinator-backed startup.
Score Breakdown
Strong technical team with Pavan Kalyan Tankala's impressive background at Google and IIT Madras, indicating solid engineering capabilities. The other two founders' backgrounds are less detailed in the provided information, making it difficult to fully assess their domain expertise and founder-market fit. However, the presence of a strong technical lead is a positive sign for an AI-native platform. [Boost +1: Founder from Google]
Large addressable market in the life sciences documentation space, with a clear and significant pain point ($45M/month delay cost). The regulatory and medical writing process is inherently complex and time-consuming, making it ripe for AI disruption. The timing appears favorable with increasing adoption of AI in enterprise settings. Competitive landscape is likely emerging but not yet saturated, offering a window for a strong player. [Boost +0.5: Hot sector: ai]
Product shows promise with an AI-native approach to drafting critical regulatory documents like CTDs, CSRs, INDs, and BLAs. The stated benefit of reducing drafting time from weeks to minutes is compelling. However, the technical differentiation and defensibility/moat are not yet fully elaborated. UX quality and platform potential will be crucial for adoption and long-term success, and these aspects require further investigation.
Early stage with positive press coverage and a Y Combinator affiliation, indicating initial validation and interest. However, specific metrics on revenue, users, and growth rate are not provided, making it challenging to assess current traction beyond early buzz. Partnerships and investor interest are also not detailed, suggesting a need for more concrete evidence of market adoption. [Boost +3: Tier-1 VC: accel; Revenue/ARR mentioned]
News
Ritivel has launched an AI-native workspace designed to help regulatory and medical writing teams in life sciences companies draft regulatory documents like CTDs, CSRs, INDs, and BLAs significantly faster.
Ritivel, a San Francisco-based startup founded in 2025, provides AI-powered regulatory platforms for the life sciences sector, having raised $500K in funding.
Ritivel has launched an AI-native workspace designed to help regulatory and medical writing teams in life sciences companies draft FDA documents like CTDs, CSRs, INDs, and BLAs significantly faster.
Ritivel AI is addressing the significant bottleneck in pharmaceutical regulatory submissions by using traceable generative AI to automate the drafting of complex documents like Clinical Study Reports and Common Technical Documents, aiming to reduce delays and associated revenue losses.
Ritivel offers an AI-native workspace for regulatory and medical writing teams in life sciences, enabling them to draft complex documents like CTDs, CSRs, INDs, and BLAs in minutes instead of weeks.
Ritivel offers an AI-native platform for regulatory and medical writing teams in life sciences, designed to significantly speed up the creation of regulatory submissions like CTDs, CSRs, INDs, and BLAs.
Ritivel provides an AI-native regulatory platform for life sciences companies, focusing on faster submissions, fewer review cycles, and enhanced accuracy and traceability for documents like Clinical Study Reports and CTD modules, with a strong emphasis on data security through local deployment.
Ritivel is an AI-native workspace for regulatory and medical writing teams at life sciences companies, enabling them to draft regulatory documents like CTDs, CSRs, INDs, and BLAs in minutes instead of weeks.
Ritivel, founded in 2025, is a seed-stage company based in San Francisco that develops an AI regulatory platform for life sciences submissions, having raised $500K in funding.
Quick Info
- Batch
- Winter 2026
- Team Size
- 3
- Location
- San Francisco, CA, USA
- Founders
- 3
- Scraped
- 4/10/2026